keynote-b61: first-line lenvatinib pembrolizumab in non-clear cell rcc
Published 1 year ago • 118 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
5:00
keynote-b61: putting a focus on non-clear cell rcc treatment
-
5:29
drs. lee, mckay on keynote-b61 for non-clear cell rcc
-
2:04
keynote-b61: extended follow-up analysis
-
13:28
keynote-b61 study results and a focus on non-clear cell kidney cancer
-
0:49
clear: lenvatinib and pembrolizumab in advanced renal cell carcinoma
-
1:14
dr. jonasch on single-agent pembrolizumab in non-clear cell rcc
-
8:05
session 5: cabosun ii & keynote-b61 results for non-clear cell rcc| dr kunal jonbanputra, moc mumbai
-
1:20
promising results of cabozantinib plus nivolumab in non-clear cell rcc
-
2:41
leap-011: exploring first-line pembrolizumab lenvatinib for advanced urothelial carcinoma
-
32:46
lenvatinib pembrolizumab in rcc, the clear trial with karine tawagi
-
2:32
len pembro metastatic clear cell renal cell carcinoma
-
1:44
assessing lenvatinib with pembrolizumab in advanced renal cell carcinoma
-
2:46
keynote-427 updates: first-line pembrolizumab monotherapy in patients with advanced clear cell r...
-
2:06
lenvatinib plus pembro for arcc - update on the clear study
-
1:17
treating non-clear cell renal cell carcinoma patients
-
1:58
subgroup analyses in the clear study of lenvatinib plus pembrolizumab versus sunitinib in rcc
-
4:57
review of the data of frontline treatment for non-clear cell kidney cancer
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc